Current Research Studies

We are currently enrolling patients to evaluate the efficacy and the safety of repeat dosing of an FDA approved benralizumab versus placebo on top of standard of care asthma therapy.

Potential Subjects must meet the following criteria:

• Between the ages of 18 and 75
• History of at least TWO asthma exacerbations that required treatment with prednisone (PO or IM) in the past 12 months.
• Documented current treatment with HIGH daily doses of ICS (Qvar, Pulmicort, Flovent…)plus at least one other asthma controller(Singulair, theophylline, Zyflo), ICS/LABA (Symbicort, Advair, Dulera, Breo), LABA (Striverdi) or LAMA(Spiriva) for at least 3 months prior to Visit 1 with a severe asthma diagnosis for at least one year.
• Eosinophil count of ≥150cells/µL
• FEV₁ of <80%

We are currently enrolling patients to evaluate the efficacy and safety of a biologic in adults and adolescents with severe, uncontrolled asthma on an ICS and at least one add’l asthma controller.

Potential subjects must meet the following criteria:

• Between the ages of 12 and 80
• History of at least TWO asthma exacerbations that required treatment with prednisone (PO or IM) in the past 12 months or hospitalization due to asthma
• Documented treatment with medium or high doses of ICS or ICS/LABA for at least three months
• PRE FEV₁ of <80% (ages18-80) or <90% (ages 12-17)
• POST Documented historical reversibility of FEV₁ ≥ 12%
• Documented treatment with at least one other asthma controller for at least three months LABA (Striverdi), LAMA (Spiriva), LTRA (Singulair), theophylline, etc.

We are currently enrolling patients to evaluate the efficacy and safety of an oral medication in participants, who have either refractory or unexplained chronic cough.

Potential subjects must meet the following criteria:

• ≥ 18 years old
• Chronic cough for ≥ 1 year and a diagnosis of refractory cough or unexplained chronic cough
• X-ray or CT scan of the thorax (within 5 years of screening/visit 1 and after onset of chronic cough)
• Have a score of ≥ 40mm on cough severity VAS at both Screening and Baseline visits
• Nonsmoker
• FEV₁/FVC ratio >60% within last 12 months while clinically stable (not during upper respiratory infection)
• Not using ACE inhibitors within 3 months of Screening/Visit 1
• NO history of adverse drug reaction or anaphylaxis to sulfonamides

The objective of this study is to describe patient characteristics, treatment patterns, and outcomes among adults with severe asthma who are not controlled with ICS or monoclonal therapy.

Potential subjects must meet the following criteria:

1. ≥ 18 years old
2. Severe asthma for at least 12 months prior to enrollment
3. Currently receiving care from our practice
4. Meeting at least ONE of the following three criteria (1, 2, or 3)
   1. Uncontrolled asthma on highest dose of ICS or ICS/LABA
   2. Current use of FDA approved biologic for treatment of severe asthma (Xolair, Cinqair, Nucala, Fasenra)
   3. Use of prednisone or other immunosuppressant for approximately 50% or more of last 12 months for treatment of severe asthma

Uncontrolled Asthma is defined as one of the following:
1. Poor symptom control ACQ >1.5, ACT <20
2. Frequent sever exacerbations: 2 or more burst of prednisone in last 12 months.
3. Severe exacerbation: at lease one hospitalization, ICU or ventilator in last 12 months.
4. FEV₁ <80%

To inquire about volunteer opportunities email us at research@allergicdisease.com